MediciNova (NASDAQ:MNOV – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Risk & Volatility
MediciNova has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for MediciNova and Collegium Pharmaceutical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| Collegium Pharmaceutical | 1 | 1 | 7 | 1 | 2.80 |
MediciNova currently has a consensus target price of $7.75, indicating a potential upside of 430.82%. Collegium Pharmaceutical has a consensus target price of $44.88, indicating a potential upside of 80.69%. Given MediciNova’s higher possible upside, research analysts clearly believe MediciNova is more favorable than Collegium Pharmaceutical.
Profitability
This table compares MediciNova and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
Institutional & Insider Ownership
9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares MediciNova and Collegium Pharmaceutical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $920,481.00 | 78.07 | -$12.00 million | ($0.21) | -6.95 |
| Collegium Pharmaceutical | $780.57 million | 1.04 | $62.87 million | $1.00 | 24.84 |
Collegium Pharmaceutical has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Collegium Pharmaceutical beats MediciNova on 10 of the 14 factors compared between the two stocks.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
